Polymorphs of olanzapine hydrochloride
The present invention relates to new crystalline forms I, II and III of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]-benzodiazepine hydrochloride, a process for the preparation thereof and pharmaceutical compositions containing the same. Said new polymorphic forms are useful as active ingredients for the treatment of psychotic conditions.
1. Crystalline form I of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]-benzodiazepine dihydrochloride, wherein the X-ray powder diffraction data and pattern are shown in Table 1 and FIG. 1 , respectively, measured using CuK α radiation:
TABLE 1
Position of diffraction lines and
relative intensities (>5%)
Peak
2*th
D(hkl)
I(abs)
I(rel)
No.
[degree]
[Å]
[cts]
[%]
1
10.38
8.5918
1017
66.47
2
12.28
7.2072
89
5.82
3
12.59
7.0305
303
19.80
4
16.31
5.4338
108
7.06
5
17.13
5.1770
693
45.29
6
18.21
4.8707
158
10.33
7
18.40
4.8219
240
15.69
8
19.38
4.5802
264
17.25
9
20.62
4.3079
1530
100
10
21.07
4.2157
199
13.01
11
22.05
4.0320
424
27.71
12
23.50
3.7862
170
11.11
13
23.85
3.7314
432
28.24
14
24.39
3.6494
142
9.28
15
25.10
3.5474
518
33.86
16
25.88
3.4434
547
35.75
17
28.06
3.1805
309
20.20
18
30.26
2.9536
199
13.01
19
30.80
2.9028
115
7.52
20
31.05
2.8803
152
9.93
21
31.17
2.8695
163
10.65
22
32.77
2.7328
148
9.67
23
33.17
2.7009
136
8.89
24
33.31
2.6895
154
10.07.
2. A process for preparation of crystalline form I of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]-benzodiazepine dihydrochloride, said process comprising:
a) dissolving 2-methyl-4-(4-methyl-piperazin-1-yl)-10H-thieno [2,3-b][1,5]-benzodiazepine base in a dipolar aprotic or less polar aprotic or protic solvent or in a mixture of such solvents, reacting the solution with a solution of a dipolar aprotic or less polar aprotic or polar solvent or a mixture of such solvents saturated with gaseous hydrogen chloride and isolating the separated crystalline polymorph, or
b) recrystallizing polymorph form II of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]-benzodiazepine dihydrochloride or a mixture of polymorph forms I and II from a protic solvent, or
c) stirring polymorph form II of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno [2,3-b][1,5]-benzodiazepine dihydrochloride or a mixture of polymorph forms I and II in a protic solvent at about room temperature and isolating the crystalline polymorph.
3. The process according to claim 2 , which comprises using a dipolar aprotic solvent, said solvent being a ketone, an ester, a dialkyl amide, or a mixture thereof.
4. The process according to claim 2 , which comprises using a less polar aprotic solvent, said less polar aprotic solvent being an ether.
5. The process according to claim 2 , which comprises using a protic solvent of a lower aliphatic alcohol.
6. A method for antipsychotic treatment, which comprises administering to the patient in need of such treatment a pharmaceutically efficient amount of crystalline form I of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]-benzodiazepine dihydrochloride.
7. Crystalline form II of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]-benzodiazepine dihydrochloride, wherein the X-ray powder diffraction data and pattern are shown in Table 2 and FIG. 2 , respectively, measured using CuK α radiation:
TABLE 2
Position of diffraction lines and
relative intensities (>5%)
Peak
2*th
D(hkl)
I(abs)
I(rel)
Number
[degree]
[Å]
[cts]
[%]
1
7.78
11.3638
219
8.74
2
8.17
10.8222
124
4.95
3
8.79
10.0557
2505
100
4
11.26
7.8611
143
5.71
5
15.54
5.7012
265
10.58
6
16.28
5.4444
478
19.08
7
17.55
5.0524
817
32.61
8
19.78
4.4885
933
37.25
9
22.26
3.9945
153
6.11
10
24.51
3.6315
348
13.89
11
25.75
3.4605
202
8.06
12
25.93
3.4362
131
5.23
13
31.30
2.8580
558
22.28
14
31.53
2.8375
202
8.06
15
32.38
2.7651
145
5.79
16
32.74
2.7355
404
16.13.
8. A process for the preparation of crystalline form II of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]-benzodiazepine dihydrochloride, said process comprising:
recrystallizing crystalline form I of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]-benzodiazepine dihydrochloride from a mixture of a dipolar aprotic or protic solvent formed with water.
9. The process according to claim 8 , which comprises using as ketone as a dipolar aprotic solvent.
10. The process according to claim 8 , which comprises using a protic solvent of a lower aliphatic alcohol.
11. A method for antipsychotic treatment, which comprises administering to the patient in need of such treatment a pharmaceutically efficient amount of crystalline form II of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]-benzodiazepine dihydrochloride.
12. Crystalline form III of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno-[2,3-b][1,5]-benzodiazepine monohydrochloride, wherein the X-ray powder diffraction data and pattern are shown in Table 3 and FIG. 3 , respectively, measured using CuK α radiation:
TABLE 3
Position of diffraction lines and
relative intensities (>5%)
Peak
2*th
D(hkl)
I(abs)
I(rel)
Number
[degrees]
[Å]
[cts]
[%]
1
7.53
11.7415
806
77.58
2
10.41
8.4980
228
21.95
3
13.93
6.3575
798
76.79
4
14.29
6.1982
147
14.15
5
15.12
5.8598
178
17.14
6
15.93
5.5629
165
15.91
7
16.62
5.3336
1039
100
8
19.10
4.6474
1027
98.85
9
19.57
4.5362
235
22.66
10
19.89
4.4639
299
28.75
11
20.53
4.3262
125
11.99
12
21.30
4.1721
309
29.70
13
21.49
4.1351
439
42.29
14
22.09
4.0241
215
20.64
15
23.61
3.7679
855
82.30
16
24.45
3.6408
154
14.87
17
25.21
3.5327
581
55.90
18
26.33
3.3849
104
10.00
19
27.46
3.2486
259
24.90
20
28.56
3.1260
138
13.23
21
29.40
3.0376
117
11.24
22
30.25
2.9546
128
12.36
23
31.29
2.8587
116
11.13
24
31.65
2.8270
230
22.18
25
32.33
2.7691
98
9.44.
13. A process for the preparation of crystalline form III of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]-benzodiazepine monohydrochloride, which comprises:
dissolving 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]-benzodiazepine base in a dipolar aprotic or less polar aprotic solvent or mixture of such solvents,
reacting said solution with an amount of hydrogen chloride necessary for the formation of monohydrochloride, and
isolating the separated crystalline polymorph.
14. The process according to claim 13 , which comprises using the dipolar aprotic solvent, said solvent being acetonitrile, a ketone, an ester, a dialkyl amide, or a mixture thereof.
15. A method for antipsychotic treatment, which comprises administering to the patient in need of such treatment a pharmaceutically efficient amount of crystalline form III of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]-benzodiazepine monohydrochloride.
16. The process according to claim 2 , wherein said dipolar aprotic solvent is selected from the group consisting of acetone, acetonitrile, ethyl acetate, dimethyl formamide and a mixture thereof.
17. The process according to claim 2 , wherein said less polar aprotic solvent is selected from the group consisting of diethyl ether, dioxane, tetrahydrofuran, diisopropyl ether and a mixture thereof.
18. The process according to claim 2 , wherein said protic solvent is selected from the group consisting of methanol, ethanol, propanol and 2-propanol.
19. The process according to claim 8 , wherein said dipolar aprotic solvent is acetone or acetonitrile.
20. The process according to claim 8 , wherein said protic solvent is ethanol or isopropanol.
21. The process according to claim 13 , wherein said dipolar aprotic solvent is selected from the group consisting of acetone, ethyl acetate, dimethyl formamide and a mixture thereof.